IOVANCE BIOTHERAPEUTICS, INC.
Last · NASDAQ$14.21-0.29 (-2.00%)close · yahoo · 16h ago
Market cap$6.44B453.0M sh
P/E · TTM-20.6fwd -72.6 · eps -0.69 · loss
Beta0.76vs S&P 500
Div yield0.00%annual · TTM
52w range
$1.76$15.30
Volume10.6Msession
| Revenue | $170.7M |
|---|---|
| Operating income | $-132.9M |
| Net income | $-126.4M |
| Free cash flow | $-145.0M |
| Operating margin | -77.9% |
| Net margin | -74.0% |
| Return on equity | -17.2% |
| Period | 2026 |
Loading chart…
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.09
Est. revenue
115.0M
Earnings transcripts
Press & signals
- GlobeNewswire
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
- GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags